Nutriband (NASDAQ:NTRB) Announces Quarterly Earnings Results, Misses Expectations By $1.95 EPS

Key Points

• Nutriband (NASDAQ:NTRB) reported a quarterly earnings loss of ($2.12) per share, missing expectations by ($1.95) EPS.
• The company's stock decreased by 2.9%, closing at $6.08 after trading 13,528 shares, significantly lower than its average volume.
• Nutriband has a market capitalization of $67.79 million and operates with a negative net margin of 415.93% and return on equity of 68.25%.

Nutriband (NASDAQ:NTRB - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($2.12) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($1.95), Zacks reports. The company had revenue of $0.62 million for the quarter, compared to analysts' expectations of $0.71 million. Nutriband had a negative return on equity of 85.40% and a negative net margin of 398.29%.

Nutriband Stock Up 3.2%

Shares of NASDAQ:NTRB traded up $0.22 during trading on Friday, hitting $7.15. 18,318 shares of the company were exchanged, compared to its average volume of 32,104. The stock has a market capitalization of $86.05 million, a P/E ratio of -2.49 and a beta of 1.13. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.78 and a quick ratio of 3.48. Nutriband has a 12-month low of $3.72 and a 12-month high of $11.78. The firm's 50 day moving average price is $7.15 and its 200-day moving average price is $6.71.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.